Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange

Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to…

Introducing Dr. Jeffrey Liebmann

Dr. Jeffrey Liebmann, a renowned ophthalmologist with years of experience in treating degenerative eye diseases, has been nominated to join the Board of Directors at Curative Biotechnology Inc. His expertise and knowledge in the field will be invaluable as the company continues to develop groundbreaking treatments for patients.

Dr. Liebmann’s appointment as an independent director will become effective upon approval by and listing of the company’s common stock on a National Exchange. This strategic move reflects Curative Biotech’s commitment to attracting top talent to drive its mission of improving the lives of those affected by degenerative eye diseases.

Impact on Individuals

As a shareholder or potential investor in Curative Biotechnology Inc., the nomination of Dr. Jeffrey Liebmann to the Board of Directors signifies a significant step towards enhancing the company’s research and development capabilities. Dr. Liebmann’s expertise will likely lead to the advancement of innovative treatments for degenerative eye diseases, potentially improving treatment options and outcomes for individuals battling these conditions.

Impact on the World

Curative Biotechnology Inc.’s nomination of Dr. Jeffrey Liebmann to their Board of Directors has broader implications for the world of biomedical research and treatment. By bringing in a prominent figure in the field of ophthalmology, the company is positioning itself to make a positive impact on global healthcare by developing novel therapies that could benefit individuals worldwide. This strategic move underscores Curative Biotech’s commitment to driving innovation and improving patient outcomes on a global scale.

Conclusion

The nomination of Dr. Jeffrey Liebmann to the Board of Directors at Curative Biotechnology Inc. is a significant development that holds promise for both individuals affected by degenerative eye diseases and the broader world of biomedical research and treatment. As the company continues to focus on developing novel therapies, Dr. Liebmann’s expertise will play a crucial role in driving innovation and improving patient outcomes. With this strategic appointment, Curative Biotech is poised to make a lasting impact on the healthcare industry and the lives of individuals worldwide.